Introduction {#sec1-1}
============

Basal cell carcinoma (BCC) is the most common human cancer in the world, but it is rarely metastatic.\[[@ref1]\] BCC etiology is attributed to epidermal stem cells of the hair follicle in the outer root sheath.\[[@ref2]\] Main molecular pathways have been identified which work in BCC.\[[@ref3]\] BCC is slow growing with a low infiltration rate and rare metastasis. Attenuated growth and infrequent metastasis invite exploration of possible key embryonic and metastatic genes.\[[@ref4]\] Implicated signaling pathways and associated target genes cannot solely explain the low proliferation rate and lack of metastasis in BCC.\[[@ref3]\] Multiple mechanisms contribute to metastasis formation, and metastasis master genes are the focus of many researchers.\[[@ref4][@ref5]\]

*Sox2* is an iconic transcription factor for the maintenance of cancer stem cells (CSCs) and acts as a fast reset button for stem cell induction and metastasis.\[[@ref6][@ref7][@ref8]\] Interestingly, silencing *sox2* reverses epithelial-mesenchymal transition (EMT).\[[@ref9]\] CSCs are engaged in progression, metastasis and relapse after treatment among the bulk of cancer cells.\[[@ref10]\] EMT and CSCs are interrelated and have led researchers to investigate a possible link between the EMT and the CSC phenotype.\[[@ref11]\] Epithelial cells attain the mesenchymal phenotype by several EMT-related molecules. Importantly, key regulatory transcription factors, such as zinc-finger E-box-binding homeobox 1 (zeb1), promote the early steps of metastasis for local invasion and subsequent dissemination of cancer cells.\[[@ref12]\]

The missing links between EMT and CSCs could be regulatory molecules-like the differentiation/anti-proliferation factor *p21*.\[[@ref13][@ref14]\] As an inhibitor, *p21* stops the cell cycle, growth and apoptosis, and as a transcription factor, *p21* decreases the expression of cell cycle progression genes and increases the expression of senescence-inducing genes; *p21* has been shown to inhibit EMT by interacting with *zeb1*.\[[@ref15]\] Another cell cycle-independent function of *p21* is its ability to interact with *sox2* to suppress the generation and expansion of induced pluripotent stem cells.\[[@ref16]\]

To avoid the undesirable spread of cancer cells, elucidation of mechanisms and molecules responsible for rare metastasis in BCC may be helpful for the development of new therapeutic targets. Here, an exploration for rational explanations of the following question began: Why do all BCC types have a low rate of metastasis in comparison with other skin cancers such as melanoma and squamous cell carcinoma (SCC)? Therefore, we examined the expression of transcription factors implicated in invasive behavior of skin cancers in the rarely metastatic BCC.

Materials and Methods {#sec1-2}
=====================

 {#sec2-1}

### Patients {#sec3-1}

Twenty-seven BCC specimens otherwise destined for disposal were collected in 2015 at the Tumor Clinic and the Reconstructive Surgery Center of the Razi Dermatology Hospital, Tehran, Iran. Information was provided by dermatologists after patient consent was obtained. This study conformed to the Ethics Committee of Tehran University of Medical Sciences and the Helsinki Declaration of 1975, as revised in 2013. Our BCC samples included nineteen male and eight female patients, with an average age of 65 ± 16, and the samples consisted of twelve cases of nodular, four cases of superficial, five cases of infiltrative, three cases of micronodular, one case of adenoid, one case of metatypical, and one case of sclerotic BCC. Twelve normal skin tissues were received from cosmetic surgeries such as blepharoplasty and rhinoplasty.

### Real-time reverse transcriptase polymerase chain reaction {#sec3-2}

Total RNA was extracted using the tripure isolation reagent (Roche, Mannheim, Germany). RNA concentration was determined by the Nanodrop (Thermo Fisher, DE, USA). RNA was treated by DNase I (Promega, Madison, USA). cDNA was synthesized from 1 μg of RNA using the PrimeScript™ RT reagent (Takara Bio Inc., Shiga, Japan). Design and bioinformatics analysis of the quantitative polymerase chain reaction (PCR) primers were conducted by the public Web service for primer design of NCBI Primer-design tool \[[Table 1](#T1){ref-type="table"}\]. Quantitative real-time PCR was conducted in triplicates on a rotor gene 6000 (Corbett Robotics, Sydney, Australia) with SYBR^®^ Premix Ex Taq™ from Takara according to the manufacturer\'s protocol. According to the Pfaffl method, normalization of relative expression levels was obtained with respect to the selected housekeeper gene *gapdh* by REST-RG software.\[[@ref17]\]

###### 

Primer sequences

  Primers                     Sequence (5\'-3\')           Length (bp)
  --------------------------- ---------------------------- -------------
  *sox2* (NM_003106.3)        F: CTCGCAGACCTACATGAACGG     149
                              R: TGGAGTGGGAGGAAGAGGTAAC    
  *p21* (NM_001291549.1)      F: CCTGTCACTGTCTTGTACCCTTG   190
                              R: TTCCAGGACTGCAGGCTTC       
  *zeb1* (NM_003068.4)        F: CTCAACTACGGTCAGCCCTG      145
                              R: TTTGGGCGGTGTAGAATCAGAG    
  *gapdh* (NM_0011519648.1)   F: GGTCGGAGTCAACGGATTTG      180
                              R: CCGTTCTCAGCCTTGACGGT      

### Statistical analysis {#sec3-3}

Multivariate analysis of variance was performed by R (R Core Team, Vienna, Austria) to compare messenger RNA (mRNA) expressions between cancer patients and controls simultaneously. The receiver operator characteristic (ROC) curve determined the sensitivity and specificity of the data. A value of *P* \< 0.05 was considered as statistically significant.

Results {#sec1-3}
=======

Normalized results of the expression, relative to the expression level of *gapdh* mRNA, are presented for two distinct invasive/noninvasive BCC groups, compared with reference normal skin \[[Figure 1](#F1){ref-type="fig"}\]. BCC samples were divided into two groups based on locally invasive behavior and aggressive behavior as evaluated by a dermatopathologist; highly invasive subtypes were included in the high-risk group (infiltrative, micro-nodular, sclerotic, and metatypical) and the remaining subtypes were included in the low-risk group. Decreased *sox2* mRNA expression was significant in both low-risk group and high-risk group compared with controls; although, *zeb1* and *p21* mRNA expressions did not represent a significant difference in the low-risk group and the high-risk group compared with controls. Basal *sox2* mRNA expression level in the human skin was confirmed in this study.\[[@ref18][@ref19]\] Expression pattern of *sox2* appeared to confirm and be concordant with prior studies of *sox2*; *sox2* could strongly differentiate control from BCC according to the ROC curve \[[Figure 2](#F2){ref-type="fig"}\].

![Mean relative expression of *sox2*, *zeb1*, and *p21* in high-and low-risk basal cell carcinomas and normal skin](IJD-65-178-g001){#F1}

![Receiver operator characteristic curve shows that *sox2* strongly differentiates control from basal cell carcinoma](IJD-65-178-g002){#F2}

Discussion {#sec1-4}
==========

Ninety percent of cancer deaths are related to metastasis. BCC is one of the few cancers with rare metastasis and thus an appropriate model for investigation of innate metastatic checkpoints monopolized in BCC for survival.\[[@ref4]\] *Sox2* is a potential mediator of BCC carcinogenesis downstream of the hedgehog and the epidermal growth factor receptor (EGFR) signaling pathways.\[[@ref3]\] *Sox2* mRNA demonstrated down-regulation in the present study of nonmetastatic BCC cases. These results help to confirm the CSC theory and can propel search to further understand the causes, processes, and functions of *sox2* mRNA decreased expression in conjunction with its partners in spectrum of skin cancers. In addition, this data rationalize the use of further techniques for the investigation of protein expression to clarify the molecular mechanisms yielding EMT, stemness, and poor metastatic ability in BCC to be potentially exploited in cancers with the high rates of metastasis. Genes involved in controlling stem cell self-renewal, uncontrolled expression of which are of great importance in cancer progression, have been introduced as a new class of cancer molecular markers\[[@ref6][@ref7][@ref8][@ref10][@ref12]\]

Previous studies have demonstrated up-regulation of mRNA and protein expression level of *zeb1* in the tongue SCC by real-time PCR and immunohistochemistry\[[@ref20]\] and also in the murine model of melanoma and short-term culture of human melanoma cell lines by immunohistochemistry/Western blot and real-time PCR.\[[@ref21]\] Stelkovics *et al*. showed *p21* up-regulation in SCC compared with BCC by tissue microarray construction and immunohistochemistry.\[[@ref22]\] By immunohistochemistry, Murphy *et al*. reported earlier and higher levels of *p21* protein expression upregulation in patients with BCC after ultraviolet (UV) exposure than observed in normal skin UV exposure.\[[@ref23]\] *Sox2* gene expression deregulation has been reported in several types of human malignancies including glioblastomas,\[[@ref7]\] melanomas,\[[@ref18]\] and SCC.\[[@ref6]\] A direct correlation is reported between *sox2* protein expression and invasiveness/metastasis potential of various solid tumors. In line with such findings, it has been shown that *sox2* down-regulation can decrease the invasiveness potential of melanomas and gliomas.\[[@ref7][@ref9]\] Thus, depleted *sox2* expression in BCC suggests the poverty of CSCs in this cancer. A possible mechanism for *sox2* down-regulation could be transcriptional suppression marker histone H3 lysine 27 trimethylation (H3K27 me3) found in the *sox2* promoter in skin squamous cells.\[[@ref24]\]

Stemness gene down-regulation in BCC has been previously reported.\[[@ref4][@ref5]\] Down-regulation of *sox2* mRNA expression, similar to down-regulation of Bmi1 and Twist1, could prognostically indicate the inefficient metastatic status of a tumor and could be useful for follow-up.\[[@ref4][@ref5]\] Our results are in agreement with Patil *et al*.\[[@ref19]\] They distinguished BCC from basaloid SCCs, which is an aggressive and recurrent cancer that metastasizes to regional lymph nodes. *Sox2* immunoreactivity was 0% in BCC versus 93% in basaloid SCC. Interestingly, they reported *sox2* nuclear staining in the adjacent nonneoplastic squamous epithelium/epidermis with the strongest staining in the basal cell layer and its progressive decrease with the maturing epithelium. They suggested that unlike *sox2* potential role as a stemness marker in various cancers, *sox2* does not appear to mediate a major role in the regulation of progenitor cells from which BCCs originate.\[[@ref2][@ref3]\]

Decrease in *sox2* mRNA expression was observed in this study on BCC, a carcinoma-associated with dysregulation of both the sonic hedgehog (SHH) and EGFR pathways.\[[@ref3]\] These findings suggest, but certainly do not prove, a correlation between *sox2* mRNA decrease and an abnormality of the SHH pathway and further suggest the hypothesis that *sox2* down-regulation might be related to disruption of regulatory transcriptional networks in the maintenance of the stemness state and self-renewal by molecules with metastasis suppressor function.\[[@ref25]\] This possibility is intriguing given that both the SHH pathway and *sox2* are important in an ectodermal development, and *sox2* has previously been shown to decrease *p21* transcription, a protein which downregulates both patched and smoothened when exogenously expressed in HaCaT cells.\[[@ref26]\] Furthermore, *sox2* knockdown in pancreatic cancer cells resulted in cell growth inhibition through cell cycle arrest (not apoptosis) through the transcriptional induction of *p21* and p27\[[@ref27]\] and linking *sox2* to a downstream effector such as p53 opens the possibility that *sox2* inactivation may promote cell growth arrest through a p53-dependent pathway.*In vitro* studies indicate the p53-*p21* axis as a negative regulator of *sox2* activity. This is a plausible function given the apparent absence of *sox2* mRNA expression in several *p21* expressing cancers. We and others found no significant deregulation of *p21* in BCC.\[[@ref22]\]

Distinct tumor-initiating and metastatic cancer cells are sensitive to *sox2* inhibition, raising the hope that interfering with *sox2* signaling may also improve relapse rates and metastasis.\[[@ref6][@ref28][@ref29]\] The *sox2* gene is crucial for self-renewal and differentiation processes of embryonic stem cells. Furthermore, it has been shown that *sox2* gene expression in tissue stem cells plays a similar role *in utero*.\[[@ref28]\] As *sox2* seems to be a biological marker for the stemness state of cancer cells,\[[@ref10]\] the considerably greater expression of *sox2* in normal skin compared to BCCs provides a likely explanation for the fact that normal skin is more reliant on *sox2* than BCC. It is essential to run complementary functional, biochemical, and signal transduction studies to better understand possible *sox2* down-regulation and its underlying mechanism of action and possible associations of metastasis suppressor pathways. BCC patient samples did not demonstrate any significant correlation with *p21* and *zeb1* mRNA expression levels.
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